Beyond Efficacy: Why DMPK and Toxicology Matter Earlier Than You Think

When people hear Crown Bioscience, they often think of world-class in vivo oncology models - and for good reason. But behind every successful oncology program is something just as critical: understanding how a drug behaves in the body and whether it can do so safely.

In this CrownCast episode, host Michelle Dawn Mooney sits down with Rekha Pal, Senior Director of Scientific Engagement, and Santi Suryani Chen, Director of Business Development at Crown Bioscience, to explore where DMPK and toxicology fit into the drug discovery picture and how getting them right can save programs from costly detours.

DMPK and Toxicology: The Bridge Between Chemistry and Biology

While Crown Bioscience is renowned for its nearly 3,000 PDX models and extensive in vivo capabilities, DMPK and toxicology are what determine whether efficacy is truly meaningful. As Rekha explains, "DMPK and toxicology sit between the chemistry and biology. Before going for in vivo efficacy, we need to know what the body does to the drug as well as what the drug does to the body."

Understanding the full ADME profile - absorption, distribution, metabolism, and excretion - alongside toxicology assessment is essential for establishing therapeutic windows and ensuring drug safety before advancing to efficacy studies.

When Early Data Changes Everything

DMPK data can completely redirect a program's trajectory. Rekha shares a common scenario: "Sometimes the compound looks great in vitro and even showed in vivo tumor regression. But early DMPK work revealed very high clearance and short half-life, so that exposure barely covered the IC50 window."

In such cases, even promising efficacy data becomes misleading if the dose approaches toxicity ceilings or drug exposure is unsustainable. Santi emphasizes the importance of proper study design: "If it can be designed correctly from the start to already incorporate certain DMPK and toxicology parameters, then we can avoid having to repeat the study just to get certain data that is needed to push this into IND and into the clinic."

Strategic Prioritization for Budget-Conscious Teams

When timelines and budgets are tight, prioritizing studies that answer fundamental questions becomes essential. Single-dose PK studies combined with basic in vitro metabolism work can provide tremendous insights, including microsomal stability, plasma protein binding, and preliminary safety screens.

Santi advises teams to "expect the unexpected" and design studies with built-in flexibility: "If you already start with the expectation of unexpected things, you're always ready to pivot and optimize as data comes through." Adding satellite arms for PK/PD analysis to efficacy studies can answer multiple questions simultaneously, avoiding costly study repetitions.

The Path Forward: Integration and Partnership

The most experienced teams use PK data to drive dose selection, study duration, and route of administration decisions from the outset. By integrating DMPK and toxicology considerations early, drug developers can correlate tumor growth inhibition with drug concentration and build predictive biomarker hypotheses.

Crown Bioscience's integrated approach, combining extensive model systems with DMPK and toxicology expertise across global locations, helps development teams design smarter studies that save both time and money while advancing toward the clinic more efficiently.